The effects of fexofenadine at steady-state on sleep architecture: A study using polysomnography in healthy Korean volunteers

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 10, 2008, Pages 1655-1665

  Lee, Ho Won ^a   Lee, Hae Won ^a   Park, Dae Jin ^b   Moon, Sung Ok ^a   Ahn, Ju Hee ^a   Kim, Mi Jin ^a   Kim, Sung Doo ^a   Kim, Ji Eun ^c   Yoon, Young Ran ^a,d  

^a Kyungpook National University Hospital   (South Korea)

^b Kosin University College of Medicine   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Kyungpook National University School of Medicine   (South Korea)

Author keywords

Antihistamines; Fexofenadine; MDR1; Polysomnography; Sleep; Steady state

Indexed keywords

CHLORPHENIRAMINE; FEXOFENADINE; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAYTIME SOMNOLENCE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NIGHT SLEEP; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP; SOUTH KOREA; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; CHLORPHENIRAMINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GENOTYPE; HALF-LIFE; HISTAMINE H1 ANTAGONISTS; HUMANS; KOREA; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; SLEEP; SLEEP, REM; TERFENADINE;

EID: 48049091557     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.10.1655     Document Type: Article

References (50)

1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351(9111):1225-32
2. Timmerman H. Factors involved in the absence of sedative effects by the second-generation antihistamines. Allergy 2000;55(Suppl 60):5-10
3. Schwartz JC, Arrang JM, Garbarg M, et al. Histaminergic transmission in the mammalian brain. Physiol Rev 1991;71(1):1-51
4. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev 2003;4(2):121-30
5. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59(2):301-21
6. Ellis AK, Day JH. Second- and third-generation antihistamines. Dermatol Ther 2000;13:327-36
7. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Int Med 2000;132(5):354-63
8. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003;111(5):S835-42
9. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ 2000;320(7243):1184-6
10. Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999;29(Suppl 3):133-42
11. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002;32(1):133-9
12. Chishty M, Reichel A, Siva J, et al. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target 2001;9(3):223-8
13. Knutsen T, Mickley LA, Ried T, et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 1998;23(1):44-54
14. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003;4(4):397-410
15. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234(1):4-33
16. Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 2007;113(1):1-15
17. Assessment. techniques associated with the diagnosis and management of sleep disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1992;42(2):269-75
18. Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002;25(6):677-9
19. Roehrs T, Roth T. Multiple Sleep Latency Test: technical aspects and normal values. J Clin Neurophysiol 1992;9(1):63-7
20. Boyle J, Eriksson M, Stanley N, et al. Allergy medication in Japanese volunteers: treatment effect of single doses on nocturnal sleep architecture and next day residual effects. Curr Med Res Opin 2006;22(7):1343-51
21. Shon JH, Yoon YR, Hong WS, et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 2005;78(2):191-201
22. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington DC: Public health service, US Government Office; 1968
23. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15(2):173-84
24. Lee HW, Jung DK, Suh CK, et al. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up. Epilepsy Behav 2006;8(4):736-41
25. Park SP, Hwang YH, Lee HW, et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008;12(1):102-8
26. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22(5):667-89
27. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97(7):3473-8
28. Spaeth J, Klimek L, Mosges R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996;51(12):893-906
29. Hindmarch I. Psychometric aspects of antihistamines. Allergy 1995;50(24 Suppl):48-54
30. Simons FE, Fraser TG, Reggin JD, Simons KJ. Individual differences in central nervous system response to antihistamines (H1-receptor antagonists). Ann Allergy Asthma Immunol 1995;75(6 Pt 1):507-14
31. Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999;57(1):31-47
32. Orr WC. Utilization of polysomnography in the assessment of sleep disorders. Med Clin North Am 1985;69(6):1153-67
33. Wise MS. Objective measures of sleepiness and wakefulness: application to the real world? J Clin Neurophysiol 2006;23:39-49
34. Theunissen EL, Vermeeren A, Ramaekers JG. Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance. Br J Clin Pharmacol 2006;61:79-86
35. Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:511-15
36. Hindmarch I, Shamsi Z, Stanley N, Fairweather DB. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999;48(2)200-6
37. Bower FA, Moore JL, Moss M, et al. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med 2003;74(2):145-52
38. Tagawa M, Kano M, Okamura N, et al. Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration. Br J Clin Pharmacol 2002;53:296-304
39. Robbins DK, Castles MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998;19(7):455-63
40. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998;64(6):612-21
41. Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27(8):866-71
42. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8
43. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002;54(10):1295-310
44. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75(1):13-33
45. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004;43(9):553-76
46. Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003;58(12):809-12
47. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001;18(10):1400-4
48. Yi SY, Hong KS, Lim HS, et al. A variant 2677A allele of the MDR1 gene affects fixofenadine disposition. Clin Pharmacol Ther 2004;76(5):418-27
49. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53(5):526-34
50. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70(2):189-99